Pharma & Biotech Mergers & Acquisitions News
Biotechnology
US Pharma major AbbVie has reached a definitive agreement to acquire Aliada Therapeutics, a biotech advancing therapies using a novel blood-brain barrier (BBB)-crossing technology to address challenging central nervous system (CNS) diseases. 29 October 2024
Today's issue
Refine Search
Latest Mergers & Acquisitions News & Features
Biotechnology
AlloVir has entered into a definitive agreement to merge with biopharma company Kalaris Therapeutics. 8 November 2024
Pharmaceutical
European regulators will decide by December 6 whether Novo Holdings, the controlling shareholder of Danish pharma giant Novo Nordisk, can finalize its $16.5 billion acquisition of contract drug manufacturer Catalent. 5 November 2024
Biotechnology
California, USA-based biotech Nektar Therapeutics’ shares closed up more than 8% at $1.33 yesterday after it announced the sale of its only manufacturing facility. 5 November 2024
Pharmaceutical
Pharmaceutical M&A came back with a bang during October, after a quiet September. 5 November 2024
Pharmaceutical
US pharma major AbbVie last week proposed $1.4 billion acquisition of US CNS drug developer Aliada Therapeutics. Last week saw a bunch of third quarter 2024 financials results, among which were Elil Lilly, AbbVie and Merck & Co. Also of note, Lexicon’s type I diabetes drug Zynquista faced a Food and Drug Administration (FDA) advisory committee review that resulted in largely negative vote against recommendation. 3 November 2024
Biotechnology
Maryland, USA–based glycobiology specialist GlycoMimetics has entered into an acquisition agreement with Crescent Biopharma, a privately held biotechnology company advancing a pipeline of oncology therapeutics designed to treat solid tumors. 30 October 2024
Biotechnology
German drugmaker Dr Falk Pharma GmbH today announced completion of the acquisition of Kynos Therapeutics, a clinical stage biopharmaceutical company focusing on the development of novel KMO inhibitors for acute and chronic inflammatory diseases. 29 October 2024
Biotechnology
US Pharma major AbbVie has reached a definitive agreement to acquire Aliada Therapeutics, a biotech advancing therapies using a novel blood-brain barrier (BBB)-crossing technology to address challenging central nervous system (CNS) diseases. 29 October 2024
Biotechnology
Ottimo Pharma, a biotech founded by Medicxi in 2020, has emerged from stealth mode with an executive team packed with prominent industry leaders. 28 October 2024
Biotechnology
Last week Vertex Pharmaceuticals released positive Phase III results for its suzetrigine for moderate-to-severed pain. Belgium’s UCB revealed that Swiss pharma giant Roche was terminating its collaboration on the Alzheimer’s candidate bepranemab. The UK’s health technology assessor the Institute for Health and Clinical Excellence (NICE) declined to recommend a second Alzheimer’s treatment, this time Eli Lilly’s Kisunla. Also of note, Lyell Immunopharma announced its planned acquisition of ImmPACT Bio and reprioritization of its own clinical pipeline. 27 October 2024
Biotechnology
California, USA-based Lyell Immunopharma (Nasdaq: LYEL) has entered into a definitive agreement to acquire privately-held US CAR-T company ImmPACT Bio. 26 October 2024
Biotechnology
Mumbai-based Mankind Pharma has completed its acquisition of Bharat Serums and Vaccines (BSV), adding to its portfolio in the women’s health and fertility market. 24 October 2024
Biotechnology
Ocuphire Pharma has announced its acquisition of Opus Genetics, a clinical-stage gene therapy company focused on treating inherited retinal diseases. 24 October 2024
Biotechnology
Connecticut, USA-based Modifi Biosciences today announced that the company has been acquired by pharma giant Merck & Co 23 October 2024
Pharmaceutical
Melbourne, Australia-based Telix Pharmaceuticals has announced the launch of Rhine Pharma, a subsidiary aimed at increasing global access to radiopharmaceuticals for cancer treatment and imaging. 22 October 2024
Pharmaceutical
French pharma major Sanofi has opened negotiations to sell a 50% controlling stake in its consumer health business Opella to US private equity firm Clayton Dubilier & Rice (CD&R). 21 October 2024
Pharmaceutical
Last week’s significant news included Denmark-based CNS drugmaker Lundbeck reaching agreement to acquire US firm Longboard Pharmaceuticals, along with its bexicaserin, for $2.6 billion. Also, US pharma giant Pfizer entered into a deal with TRIANA Biomedicines to develop molecular glue degraders. On the regulatory front, the US Food and Drug Administration (FDA) last week approved Novocure’s key product Optune Lua for lung cancer patients. Also, German biotech BioNTech and its US partner OncoC4 received a partial clinical hold from the FDA on the Phase III trial of gotistobart in lung cancer. The European Medicines Agency’s human health committee, CHMP, Reaffirmed its non-approval of PTC Therapeutic’s Translarna. 20 October 2024
Biotechnology
Taiwan-based REGiMMUNE, a biopharma creating immunotherapies through the power of regulatory T cells (Tregs), and France-based Kiji Therapeutics, a specialist in induced pluripotent stem cells-mesenchymal stem cells (IPSC-MSC) engineered cell therapies for inflammatory diseases, are to merge. 18 October 2024
Biotechnology
Danish CNS specialist Lundbeck today revealed that it has reached to acquire Longboard Pharmaceuticals. 15 October 2024
Biotechnology
USA-based Kezar Life Sciences announced this week that it was pausing its Phase IIb PALIZADE trial evaluating zetomipzomib in lupus nephritis (LN) following the deaths of four patients. 10 October 2024
Pharmaceutical
Investors in Akorn had a wake-up call yesterday, as Germany-based Fresenius raised doubts about its acquisition of Akorn amid a Food and Drug Administration enquiry into alleged allegations of FDA integrity requirements relating to product developments 28 February 2018
Biotechnology
The biologics arm of UK-based AstraZeneca is putting six molecules from its early-stage inflammation and autoimmunity programs at the heart of a newly formed company, called Viela Bio. 28 February 2018
Biotechnology
Honk Kong-based Golden Meditech, a diversified medtech and healthcare services firm, has acquired licenses to permit genetic testing and cell and tissue storage services in Shanghai. 26 February 2018
Biotechnology
Merck & Co has agreed to buy the Australian firm Viralytics Limited for A$1.75 per share, valuing the firm at just over half a billion Australian dollars ($394 million). 21 February 2018
Pharmaceutical
French drugmaker Ipsen has entered into a strategic agreement to develop and commercialize innovative therapies with UK-based life sciences firm Arix Bioscience. 21 February 2018
Pharmaceutical
PDL BioPharma today officially announced it will no longer pursue its proposed acquisition of US modified-release drug delivery specialist Neos Therapeutics. 20 February 2018
Pharmaceutical
A new firm dubbed Gain Therapeutics has been spun out of Barcelona’s Minoryx Therapeutics, centered around the SEE-Tx platform to develop treatments for rare metabolic diseases. 20 February 2018
Generics
Switzerland’s Novartis is mulling a sale of its generic dermatologics business, which primarily does business in the USA, according to Reuters. 19 February 2018
Biotechnology
In biotech, investors are used to hearing big pledges from start-ups about their capacity to meet needs and cure diseases, but even in this optimistic field, some of the goals set by a new US company are unusually ambitious. 16 February 2018
Pharmaceutical
Roche has signed a definitive agreement under which it will acquire all shares of Flatiron Health, following on from an existing equity stake of 12.6% via an investment of $175 million in 2016. 16 February 2018
Pharmaceutical
Charles River Laboratories International has entered into a definitive agreement to acquire MPI Research for around $800 million in cash, subject to customary closing adjustments. 14 February 2018
Biotechnology
Japanese pharma major Astellas is to pay up to $102.5 million in upfront and milestone payments to acquire Seattle-based biotech Universal Cells. 14 February 2018
Biotechnology
Celgene’s recent announcement of the acquisition of Juno Therapeutics has put the company in a good position to be a frontrunner in the chimeric antigen receptor- T cell (CAR-T) space. 13 February 2018
Biotechnology
The problem with being a cash-laden big biotech company can be that everyone knows that you are a cash-laden big biotech company. 12 February 2018
Generics
An increased dependence on the import of active pharmaceutical ingredients (APIs) from China is raising national security concerns in India, with the Health Ministry contending it is technically destroying indigenous manufacturing, reports The Pharma Letter’s India correspondent. 9 February 2018
Generics
It has emerged that the number of industry players in the running to buy Sanofi’s European generics business Zentiva has been whittled down to two. 6 February 2018
Pharmaceutical
Attracting a great deal of attention last week, was the news that Sanofi had outbid Novo Nordisk for the acquisition of Belgian biotech firm Ablynx with a 3.9 billion-euro deal, and also on the M&A front, Seattle Generics’ cheap entry into the breast cancer field with the acquisition of Cascadian Therapeutics for just $614 million. In negative news last week, there was a complete response letter from the US Food and Drug Administration for Aradigm’s Linhaliq, and disappointing financial results from AstraZeneca, with mixed ones from Roche. 4 February 2018
Pharmaceutical
Companies have not spent long sitting on cash piles freed up by the long-awaited US tax reforms after they were approved by the Senate last month. 1 February 2018
Pharmaceutical
UCB and a syndicate of Belgian and international investors have founded a new firm, Syndesi Therapeutics, to be based at the Centre d’Entreprises et d’Innovation (CEI) in Louvain-la-Neuve, Belgium. 1 February 2018
Biotechnology
The Bonn, Germany-based Life Science Inkubator is bringing to life a previously axed research project originating at Merck KGaA. 1 February 2018
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze